Celsion Reports Second Quarter 2009 Financial Results and Business Update
COLUMBIA, Md., Aug 05, 2009 (BUSINESS WIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today announced financial results for the second quarter ended June 30, 2009.
"In the second quarter of 2009 we made excellent progress towards the completion of enrollment in the ThermoDox(R) global Phase III clinical trial for primary liver cancer," commented Michael H. Tardugno, Celsion's President and Chief Executive Officer. "The rate of enrollment is consistent with our projections. We now have enrolled 151 patients, or 25% of that required to complete the study. We were pleased to recently have announced the expansion of the study to Japan under the direction of our exclusive Japanese license partner, Yakult. This will accelerate our time to approval in Japan while also providing non-diluting financing from Yakult which is in addition to an $18 million milestone payment upon Japanese approval. Under our agreement, Yakult funds the cost of patients enrolled in Japan. Our pending China CTA remains under evaluation. We continue to be optimistic that we will receive approval for our trial in the near term. In addition, we are expanding the clinical study to the Philippines, Malaysia and Thailand and expect to have 55-60 clinical sites enrolling patients by year end. Assuming additional time is required to enroll the added minimum Japanese patient cohort, enrollment could be completed in the second quarter of 2010."
"Also in the second quarter of 2009, we enrolled our first patients in the Phase I/II recurrent chest wall (RCW) breast cancer clinical trial and we announced that ThermoDox(R) was the subject of three presentations at the Society for Thermal Medicine Annual Meeting, further increasing the drug's exposure within the physician and scientific communities."
For the second quarter ended June 30, 2009, Celsion reported a net loss of $4.6 million, or $0.45 per diluted share, compared to a net loss of $2.4 million, or $0.24 per diluted share for the second quarter of 2008. For the six months ended June 30, 2009, Celsion reported a net loss of $8.2 million, or $0.81 per diluted share, compared to a net loss of $6.5 million, or $0.64 per diluted share in 2008. The Company ended the quarter with a total of $14.9 million in cash and short-term investments.
Recent Company Highlights
The Company is holding a conference call to provide a business update and discuss the second quarter 2009 results at 11:00 a.m. Eastern Time on Wednesday, August 5, 2009. To participate in the call, interested parties may dial 1-800-289-0462 (Toll-free) or 1-913-312-1415 (Toll/International) and use Conference ID: 5488524 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the Internet at http://www.celsion.com
The call will be archived for replay on August 5, 2009 at 2:00 P.M. ET and will remain available until August 12, 2009. The replay can be accessed at 1-888-203-1112 (Toll-free) or 1-719-457-0820 (Toll/International) using Conference ID: # 5488524. The call will also be available on the Company's website, http://www.celsion.com, for 30 days after 2:00 P.M. on Wednesday, August 5, 2009.
ThermoDox(R) in combination with hyperthermia has the potential to provide local tumor control and improve quality of life. ThermoDox(R) is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. Localized mild hyperthermia (39.5-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.
For primary liver cancer, ThermoDox(R) is being evaluated in a 600 patient global Phase III study under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox(R) in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival. For recurrent chest wall breast cancer, ThermoDox(R) is being evaluated in a pivotal Phase I/II open-label, dose-escalating trial that is designed to measure durable local complete response at the tumor site. Celsion expects to enroll approximately 100 patients across the United States. Additional information on these ThermoDox(R) clinical studies may be found at http://www.clinicaltrials.gov
ThermoDox(R) is a registered trademark of Celsion Corporation
Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox(R) to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.
For more information on Celsion, visit our website: http://www.celsion.com
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
Condensed Statements of Operations
(in thousands except for per share amounts)
Ended June 30,
Ended June 30,
|Research and development||$||4,230||$||1,615||$||7,172||$||4,582|
|General and administrative||602||581||1,291||1,077|
|Total operating expenses||4,832||2,196||8,463||5,659|
|Loss from operations||(4,832||)||(2,196||)||(8,463||)||(5,659||)|
|Other income (expense), net||241||(234||)||255||(853||)|
|Net loss before income taxes||(4,591||)||(2,430||)||(8,208||)||(6,512||)|
|Basic and diluted net loss per common share||$||(0.45||)||$||(0.24||)||$||(0.81||)||$||(0.64||)|
|Basic and diluted weighted average shares outstanding||10,196||10,146||10,194||10,145|
(in thousands except for per share amounts)
|ASSETS||June 30, 2009 (Unaudited)|
|Cash and cash equivalents||$||12,115||$||3,456|
|Short term investments available for sale||2,830||4,061|
|Due from Boston Scientific Corporation||-||15,000|
|Prepaid expenses and other receivables||148||306|
|Total current assets||15,093||22,823|
|Property and equipment||227||223|
|Total other assets||913||642|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable - trade||$||3,139||$||1,187|
|Other accrued liabilities||1,435||1,459|
|Note payable - current portion||-||235|
|Total current liabilities||4,574||3,934|
|Other liabilities - noncurrent||22||28|
|Common stock - $0.01 par value (75,000,000 and 250,000,000 shares authorized; 10,856,088 and 10,816,088 shares issued: 10,095,814 and 10,156,350 shares outstanding at June 30, 2009 and December 31, 2008, respectively)||109||108|
|Additional paid-in capital||89,737||89,183|
|Less: Treasury stock - at cost||(3,077)||(2,641)|
|Total stockholders' equity||11,637||19,726|
|Total liabilities and stockholders' equity||$||16,233||$||23,688|
SOURCE: Celsion Corporation
Sean Moran, 410-290-5390
Senior Vice President and Chief Financial Officer
The Trout Group
Marcy Nanus, 646-378-2927
Copyright Business Wire 2009